Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Maria Soler Nunez appointed as Head, Group Operations: https://mailing-ircockpit.eqs.com/crm-mailing/5b71ace0-ea7c-11e8-902f-2c44fd856d8c/da75bbed-f3bc-4a1d-9875-d27419257884/44372190-575f-48fc-882c-357bfd2721ce/MSN.jpg
Maria Soler Nunez appointed as Head, Group Operations
Maria Soler Nunez appointed as Head, Group Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=4d0c5b6b32708f0543d895c3b29a2277
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics announces the appointment of its new Scientific Advisory Board

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a9745ad9af6824f7d988e3dabb8be4ea
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
THERANEXUS PARTICIPATES IN SEVERAL LEADING SCIENTIFIC CONFERENCES AND BUSINESS CONVENTIONS

Lyon, France – 9 June 2022– 6 pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the

Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=a2e20e899e5ab994754dd16899a8a74c
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=76e2f0335d941bedb39fe6be92218959
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed

Caissargues, May 12, 2022

 

In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%

 

 

Group

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development

QUANTUM GENOMICS : Publication of the Universal Registration Document

Publication of the Universal Registration Document

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the

QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise

Update of Shareholding Situation Following April 27, 2022 Capital Raise

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a

Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR

Quantum Genomics announces successful capital raising with a gross sum of approximately €15.6 M€

  • Quantum Genomics has equipped itself with new financial means to pursue the development of
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

  • Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

BOIRON : 2022 first quarter sales

(Unaudited data)

In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new

QUANTUM GENOMICS : Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new

BOIRON : 2021 results

The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31

THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
  • · New milestone for NeuroLead, the active agent screening platform
  • · New publications in scientific journals
  • · Start of Phase I/II clinical trial for Batten disease

Lyon, 28 February 2022

THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS

Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates

BOIRON : 2021 sales

(Unaudited data)

QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)

in thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter 2021 2020 Var. 2021
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE

Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction